Free Trial
NASDAQ:EYEN

Eyenovia Q4 2024 Earnings Report

Eyenovia logo
$1.13 +0.04 (+3.67%)
Closing price 04/28/2025 03:55 PM Eastern
Extended Trading
$1.10 -0.03 (-3.10%)
As of 04/28/2025 06:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eyenovia EPS Results

Actual EPS
N/A
Consensus EPS
-$7.20
Beat/Miss
N/A
One Year Ago EPS
N/A

Eyenovia Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.60 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eyenovia Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Earnings Documents

Eyenovia Earnings Headlines

Eyenovia provides development update on Optejet UFD
Real Americans Don’t Wait on Wall Street’s Next Move
What's happening in the markets right now should concern every freedom-loving American who's worked hard and saved smart. Your 401(k) doesn't deserve to be dragged through the mud by tariffs, trade wars, reckless spending, and political standoffs. And you don't have to stand by while Wall Street plays roulette with your future.
Eyenovia enters non-binding LOI to effect reverse merger with Betaliq
Eyenovia Shares Drop 14% Amid Betaliq Merger Talks
See More Eyenovia Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eyenovia? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eyenovia and other key companies, straight to your email.

About Eyenovia

Eyenovia (NASDAQ:EYEN), an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

View Eyenovia Profile

More Earnings Resources from MarketBeat